LRMR Larimar Therapeutics, Inc.

8-K Current Report

Filed: February 27, 2026

Health Care

Pharmaceutical Preparations

Larimar Therapeutics, Inc. (LRMR) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Larimar priced public offering of 20M shares at $5.00/share; underwriters exercised full 3M share overallotment on Feb 26, 2026
• Total shares sold: 23M; net proceeds ~$107.6M after underwriting discounts and estimated expenses

+2 more insights

Other Larimar Therapeutics, Inc. 8-K Filings

8-K Mar 19, 2026

8-K Mar 9, 2026

8-K Feb 24, 2026

Get deeper insights on Larimar Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.